6533b870fe1ef96bd12d069e

RESEARCH PRODUCT

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

Günter KrämerG. P. MengeK. D. StollB. TettenbornP. Klosterskov Jensen

subject

DrugAdultMalemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentOxcarbazepinePharmacologymedicineHumansDrug InteractionsOxcarbazepineBlood Coagulationmedia_commonProthrombin timeChemotherapymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnticoagulantWarfarinDose–response relationshipAnticonvulsantCarbamazepineNeurologyAnesthesiaProthrombin TimeAnticonvulsantsNeurology (clinical)Warfarinbusinessmedicine.drug

description

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

yearjournalcountryeditionlanguage
1992-11-01Epilepsia
10.1111/j.1528-1157.1992.tb01772.xhttps://pubmed.ncbi.nlm.nih.gov/1464277